Cephalon Inc. / Salmedix, Inc.

Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Disease Overview

Indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL) are slow-growing B-cell malignancies. While generally treatable, they are typically incurable, and patients eventually relapse on rituximab-containing regimens. Bendamustine is a bifunctional alkylating agent with mechanistic features distinct from cyclophosphamide and chlorambucil that proved highly effective in the rituximab-refractory setting.

Competitive Landscape

At the May 2005 deal close, the iNHL/CLL standard of care was R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone) or chlorambucil monotherapy in older CLL patients. Bendamustine had been marketed in Germany since the 1970s as Ribomustin (Ribosepharm/Astellas) for multiple myeloma and lymphomas, but had no US presence. Salmedix had in-licensed US/Canada rights and put SDX-105 through Phase 2 in rituximab-refractory iNHL. Cephalon's $160M cash plus $40M contingent acquisition was a calculated bet on a known-mechanism European drug filling a US gap. FDA approved Treanda in March 2008 for CLL and October 2008 for rituximab-refractory iNHL. Pivotal data subsequently showed bendamustine-rituximab (BR) more than doubled progression-free survival vs. R-CHOP with better tolerability, establishing BR as a new front-line standard. Treanda became a >$700M Cephalon franchise (later reformulated as Bendeka by Eagle/Teva) and is widely cited as one of the most successful small-biotech buyouts of the 2000s before the Phase 3 ibrutinib (Imbruvica) and venetoclax (Venclexta) era reshaped CLL. Competing alkylators included chlorambucil (Leukeran) and cyclophosphamide; later entrants displacing BR included BTK inhibitors and BCL-2 inhibitors.